Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	May 31, 2016	May 31, 2015	May 31, 2014
Net sales	$ 379,972	$ 389,300	$ 388,056
Cost of sales (exclusive of amortization shown separately below)	143,969	143,659	139,634
Gross profit	236,003	245,641	248,422
Operating expenses:
Research and development	30,255	28,791	29,070
Selling and marketing	56,655	57,833	59,057
Distribution	17,462	20,022	20,165
General and administrative	44,462	41,191	41,603
Amortization expense	54,937	54,531	52,965
Acquisition-related items			(4,638)
Asset impairment loss	3,318		160,150
Total operating expenses	207,089	202,368	358,372
Income (loss) from operations	28,914	43,273	(109,950)
Non-operating (expense) income:
Interest income	135	145	36
Interest expense	(90,535)	(89,421)	(88,304)
Other, net	(244)	878	45
Total non-operating net expense	(90,644)	(88,398)	(88,223)
Loss before income taxes	(61,730)	(45,125)	(198,173)
(Benefit) provision for income taxes	(17,963)	15,600	(15,916)
Net loss	(43,767)	(60,725)	(182,257)
Net loss attributable to noncontrolling interest	(1,677)
Net loss attributable to Immucor, Inc.	$ (42,090)	$ (60,725)	$ (182,257)